Netherlands-based venture capital firm Forbion Capital Partners has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III (FCF III); its target is €150 to €200 million. Forbion will be looking to invest in companies developing medical devices, companion diagnostics, and innovative therapeutics. A spokesperson for the venture capital firm said that it had no specific therapeutic areas of interest, "although many of the therapeutic investee companies are focused on cancer."
Forbion’s New Fund
Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.